Key Highlights
- FDA grants approval for Eli Lilly’s orforglipron, marketed as Foundayo, a once-daily oral weight-loss medication
- April 6 launch scheduled through LillyDirect platform at $149 monthly for direct-pay patients
- Wall Street estimates 2026 revenues spanning $1.5B (Guggenheim) to $2.8B (Citi), with long-term peak sales surpassing $40B
- Company stockpiled $1.5B in inventory ahead of launch to prevent shortages experienced with injectable treatments
- Consensus analyst price target stands at $1,221, with predominantly Buy and Moderate Buy recommendations
Eli Lilly has achieved a significant regulatory milestone with its oral GLP-1 medication. The FDA has given the green light to orforglipron — commercially known as Foundayo — marking the pharmaceutical giant’s entry into once-daily weight-loss tablets and positioning it to compete head-to-head with Novo Nordisk’s market leadership.
JUST IN: FDA approves Eli Lilly's $LLY GLP-1 weight loss pill, Foundayo.
Ships from LillyDirect on Monday. Available at pharmacies shortly after.
Pricing: $25/month with insurance, $149-$349 out of pocket depending on dose.
The pill shows ~12.4% average weight loss vs ~16.6%… pic.twitter.com/4V8iXK9BIV
— WOLF (@WOLF_Financial) April 1, 2026
Clinical study participants using Foundayo demonstrated body weight reductions ranging from 12% to 15%. The medication works by targeting the GLP-1 hormone pathway, identical to the mechanism employed by Novo’s injectable products Ozempic and Wegovy.
Commencing April 6, Lilly will make Foundayo available through its LillyDirect distribution channel. Patients paying out-of-pocket can obtain the entry-level dosage for $149 monthly — strategically matching Ozempic’s price point.
Chief Executive David Ricks announced that Foundayo has been submitted to regulatory authorities in over 40 nations, indicating the company’s plans for an extensive global expansion.
Financial analysts have responded with optimism. Projections for 2026 revenues span from $1.5 billion to $2.8 billion, with Citi leading the bullish camp at $2.8B and forecasting ultimate annual sales exceeding $40 billion. J.P. Morgan anticipates revenues climbing to $6 billion by 2027.
Bernstein adopted a more measured short-term outlook, noting that complimentary sampling programs, initial lower dosage protocols, and pricing considerations might temper early revenue performance despite potentially robust prescription growth. The metric investors will monitor most carefully is weekly new patient enrollment.
Foundayo also benefits from production advantages. The pill format is simpler to manufacture than injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in overseas markets where injectable supply has been constrained.
Supply Lessons Learned
Lilly reports accumulating $1.5 billion in pre-launch stock, a strategic move shaped by supply shortages that affected its injectable medications Zepbound and Mounjaro. Those availability gaps created opportunities for U.S. compounding pharmacies to market alternative versions. Lilly subsequently initiated legal proceedings against compounding facilities and wellness clinics distributing products purporting to contain tirzepatide.
Novo Nordisk is mounting its own competitive response. The Copenhagen-based pharmaceutical company has introduced subscription pricing models and modified product offerings. UBS forecasts that the combined oral GLP-1 products from both manufacturers could produce approximately $5 billion in 2026 revenue, highlighting rapid expansion in this obesity treatment segment.
Morningstar anticipates that oral obesity medications could represent approximately one-third of a $180 billion worldwide market by 2034.
Acquisition and Analyst Views
Lilly is proceeding with the acquisition of Centessa Pharmaceuticals in a transaction originally valued near $6.3 billion, broadening its portfolio into sleep-wake conditions and narcolepsy treatments. A legal firm has initiated an investor investigation regarding Centessa’s sale procedures, potentially creating complications before deal completion.
On the institutional investment front, Westend Capital Management established a fresh position in LLY during Q4, acquiring 16,393 shares valued at approximately $17.6 million. LLY currently represents roughly 4.9% of Westend’s holdings.
Lilly reported Q4 earnings per share of $7.54, surpassing projections of $7.48, with quarterly revenue reaching $19.29 billion versus consensus estimates of $17.85 billion. Revenue increased 42.6% compared to the prior year. Management issued FY2026 EPS guidance ranging from $33.50 to $35.00.
Among 30 analysts tracking the equity, 23 assign Buy ratings, four recommend Hold, and one rates it Sell. The mean price target is positioned at $1,221.26.
